Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;13(4):138-145.
doi: 10.14740/gr1275. Epub 2020 Aug 14.

Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital

Affiliations

Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital

Charumathi Raghu Subramanian et al. Gastroenterology Res. 2020 Aug.

Abstract

Background: Cure rates of Clostridium difficile infection (CDI) with fecal microbiota transplant (FMT) have been promising. However, there is debate regarding success of FMT in patients with comorbidities.

Methods: Electronic chart review was done to collect data on patients who underwent FMT from January 2015 to August 2017. Charts were analyzed in November 2018 with a median follow-up of 25.4 months (interquartile range 20 - 31 months).

Results: Twenty patients underwent FMT. The primary success rate at our institution was 90% and overall success rate was 100%. Six patients (43%) had FMT failure (two early and four late).

Conclusions: This case series is a description of our center's initial experience with FMT for treatment of recurrent CDI. Our high success rate reiterates the efficacy and safety of FMT in this population including patients with comorbidities.

Keywords: Clostridium difficile infection; Fecal microbiota transplant; Inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

Dr Jeffry A Katz: 1) Prometheus Labs advisory board; 2) Boerhinger-Ingelheim advisory board. No disclosures for rest of the authors.

Figures

Figure 1
Figure 1
Response to FMT treatment. FMT: fecal microbiota transplantation.

Similar articles

References

    1. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32(4):387–390. doi: 10.1086/659156. - DOI - PubMed
    1. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med. 2008;359(18):1932–1940. doi: 10.1056/NEJMra0707500. - DOI - PubMed
    1. Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8(1):1–6. doi: 10.5009/gnl.2014.8.1.1. - DOI - PMC - PubMed
    1. Sinh P, Barrett TA, Yun L. Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterol Res Pract. 2011;2011:136064. doi: 10.1155/2011/136064. - DOI - PMC - PubMed
    1. Kelly CP. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA. 2009;301(9):954–962. doi: 10.1001/jama.2009.171. - DOI - PubMed

LinkOut - more resources